Business, energy, technology, markets and global industry news from Business News Today

ESMO 2026

PharmaDeviceNews ESMO 2026
Insilico Medicine’s ISM6331 Phase 1 study is evaluating an oral pan-TEAD inhibitor in patients with mesothelioma and other advanced solid tumors ahead of its ESMO 2026 presentation. Representative image.
Pharma & Biotech

What will Insilico Medicine reveal about ISM6331 at the ESMO 2026 Congress?

Insilico Medicine’s first human data for ISM6331 will arrive as clinical interest in TEAD inhibition is accelerating. The presentation must show whether the AI-designed molecule can combine credible antitumor activity with a dose and safety profile suitable for further development.

Read More
Pharma & Biotech

Can Brenus Pharma crack the cold-tumor problem in metastatic colorectal cancer?

Find out how Brenus Pharma’s STC-1010 FDA IND acceptance could reshape MSS colorectal cancer immunotherapy development.

Read More
Pharma & Biotech

Can Leads Biolabs turn Opamtistomig into a frontline EP-NEC treatment contender?

EP-NEC has no approved drug worldwide. Leads Biolabs now has to prove Opamtistomig can turn rare-tumor urgency into regulatory momentum.

Read More